ATHENS, Ga., March 31 /PRNewswire/ -- ArunA Biomedical, Inc., a leader in human embryonic stem cell derived products, announced today that it has been awarded a Department of Defense contract to develop an environmental biosensor utilizing its human stem cell technology.
The company will further develop a human embryonic stem cell derived cellular model for use in a prototype biosensor developed by the Naval Research Laboratory and previously studied by the
"Effective monitoring and regulation of environmental contamination remains a major challenge of great importance for both military and civilian populations," commented David Ray, ArunA CEO. "ArunA is pleased to have an opportunity to further develop a technology that could aide national security and field combat."
About ArunA Biomedical
Located in Athens, Georgia, ArunA Biomedical, Inc. is a privately held biotechnology corporation dedicated to the discovery, manufacturing and commercialization of emerging new technologies in human stem cell research for use in drug discovery and basic research. ArunA is the first company to commercialize products derived from human embryonic stem cells and sees its proprietary technology as a catalyst leading to the discovery of novel therapeutic compounds, tests for neurotoxicity and breakthroughs in understanding human development and diseases. For more information, visit: www.arunabiomedical.com
This press release contains forward-looking statements regarding the company's potential impact on scientific research and collaborations with third parties. Certain conditions could alter the outcome or progress of these statements including but not limited to unexpected manufacturing issues, product performance and quality control/assurance issues. Forward-looking statements are based on the opinions, beliefs and expectations of the company or individuals quoted in the press release and the company does not assume any obligation to update these forward-looking statements if circumstances change.
|SOURCE ArunA Biomedical, Inc.|
Copyright©2009 PR Newswire.
All rights reserved